*Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Dermatology |
|
|
|
Ulcers |
|
|
|
|
Diabetic Foot |
|
|
|
Platelet Derived Growth Factors (PDGF) |
|
|
|
| Regranex (Beclapermin) |
Lower Extremity Diabetic Neuropathic Ulcers |
Infection, Cellulitis, Osteomyelitis, Erythematous Rashes |
Approved |
|
Immunology |
|
|
|
|
Autoimmune Disorders |
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
|
Interferons |
|
|
|
| Betaseron (Interferon Beta-1b) |
Relapsing Forms Of Multiple Sclerosis To Reduce The Frequency Of Clinical Exacerbations |
Lymphopenia, Injection Site Reaction, Asthenia, Flu-Like Symptom Complex, Headache, Pain |
Approved |
| Betaseron (Interferon Beta-1b) |
Relapsing Forms Of Multiple Sclerosis To Reduce The Frequency Of Clinical Exacerbations |
Lymphopenia, Injection Site Reaction, Asthenia, Flu-Like Symptom Complex, Headache, Pain |
Approved |
|
Infectious Diseases |
|
|
|
|
Bacterial |
|
|
|
|
Antibacterial Agents |
|
|
|
|
Narrow Spectrum |
|
|
|
|
Respiratory System |
|
|
|
|
Cystic Fibrosis/Pseudomonas Aeruginosa |
|
|
|
|
Aminoglycosides |
|
|
|
| (Tobi) Inhalable Tobramycin |
Cystic Fibrosis Patients With Pseudomonas Aeruginosa Infection |
|
Phase III |
| TOBI (Tobramycin) |
Management Of Cystic Fibrosis In Patients With Pseudomonas Aeruginosa |
Increased Cough, Pharyngitis, Increased Sputum, Asthenia, Rhinitis, Dyspepsia, Fever, Voice Alteration |
Approved |
|
Pneumonia |
|
|
|
|
Tissue Factor Pathway Inhibitor (TFPI) |
|
|
|
| Tifacogin |
Severe Community-Acquired Pneumonia (SCAP) |
|
Phase III |
|
Phase I/Phase II Clinical Stage Products |
|
|
|
| Flu Cell Culture Vaccine |
Influenza Vaccine (Flu Vaccine) |
|
Phase I/II |
| HIV Vaccine |
HIV Infection |
|
Phase I |
| Hepatitis C (HCV) Vaccine |
Hepatitis C Vaccine |
|
Phase I |
| Meningococcus B Vaccine |
Broad Range Meningococcus B Vaccine |
|
Phase I |
| Multivalent (ACYW) Meningococcal Vaccine |
Meningococcal Groups A/C/Y/W-135 Vaccine |
|
Phase II |
| PA-824 |
Tuberculosis (TB) |
|
Phase I |
|
Research/Preclinical Stage Products |
|
|
|
| H9N2 Avian Influenza Vaccine |
Avian Influenza Vaccine (H0N2 Flu Vaccine) |
|
Preclinical |
|
Viral |
|
|
|
|
Vaccines |
|
|
|
|
Viral |
|
|
|
|
Single Target |
|
|
|
|
Influenza (Flu) |
|
|
|
| Fluvirin (Triple Antigen Flu Vaccine) |
Influenza Vaccine (Flu Vaccine) |
Local Inflammation Reaction At Injection Site, Fever, Malaise |
Approved |
|
Rabies |
|
|
|
| RabAvert (Rabies Vaccine) |
Pre-Exposure Immunization In Both Primary Series And Booster Dose, And For Post-Exposure Prophylaxis Against Rabies |
Pain At The Injection Site, Localized Lymphadenopathy, Malaise, Headache, And Dizziness |
Approved |
|
Neurology |
|
|
|
|
Neuromuscular Disorders |
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
|
Interferons |
|
|
|
|
Oncology |
|
|
|
|
Dermatology |
|
|
|
|
Malignant Melanoma |
|
|
|
|
Interleukins |
|
|
|
|
Interleukin-2 (IL-2) |
|
|
|
| Proleukin (Aldesleukin) |
Treatment Of Adults With Metastatic Renal Cell Carcinoma (Kidney Cancer) And Metastatic Melanoma (Skin Cancer) |
Hypotension, Diarrhea, Chills, Vomiting, Dyspnea, Bilirubinemia |
Approved |
|
Phase I/Phase II Clinical Stage Products |
|
|
|
| CHIR-12.12 (Anti-CD40) |
Advanced Chronic Lymphocytic Leukemia |
|
Phase I |
| CHIR-12.12 (Anti-CD40) |
Multiple Myeloma |
|
Phase I |
| CHIR-258 |
Solid Tumors (Cancer) |
|
Phase I |
| CHIR-258 |
Acute Myelogenous Leukemia (AML) |
|
Phase I |
| CHIR-265 |
Melanoma (Skin Cancer) |
|
Phase I |
| Proleukin (Aldesleukin) |
In Combination With Rituxan For The Treatment Of Refractory Low-Grade Non-Hodgkin's Lymphoma (NHL) |
|
Phase II |
| Proleukin (Aldesleukin) |
Rituximab-naive Patients With Non-Hodgkin's Lymphoma (NHL) Who Have Failed To Respond To Chemotherapy |
|
Phase II |
|
Urology |
|
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
|
Metastatic |
|
|
|
|
Interleukins |
|
|
|
|
Interleukin-2 (IL-2) |
|
|
|
| Proleukin (Aldesleukin) |
Treatment Of Adults With Metastatic Renal Cell Carcinoma (Kidney Cancer) And Metastatic Melanoma (Skin Cancer) |
Hypotension, Diarrhea, Chills, Vomiting, Dyspnea, Bilirubinemia |
Approved |
|
Respiratory System |
|
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
|
Cystic Fibrosis (CF) |
|
|
|
|
Complications |
|
|
|
|
Bacterial Infections |
|
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
|
Aminoglycosides |
|
|
|
| (Tobi) Inhalable Tobramycin |
Cystic Fibrosis Patients With Pseudomonas Aeruginosa Infection |
|
Phase III |
| TOBI (Tobramycin) |
Management Of Cystic Fibrosis In Patients With Pseudomonas Aeruginosa |
Increased Cough, Pharyngitis, Increased Sputum, Asthenia, Rhinitis, Dyspepsia, Fever, Voice Alteration |
Approved |
|
Phase I/Phase II Clinical Stage Products |
|
|
|
|
Transplantation |
|
|
|
|
Lung |
|
|
|
|
Rejection Prophylaxis |
|
|
|
|
Immunosuppressants |
|
|
|
| Pulminiq (Aerosolized Cyclosporine) |
Increase In Survival And Prevention Of Chronic Rejection In Patients Receiving Allogeneic Lung Transplants |
|
Approvable Letter Received |
|
Wound Management |
|
|
|
|
Ulcers |
|
|
|
|
Diabetic Foot |
|
|
|
|
Platelet Derived Growth Factors (PDGF) |
|
|
|
| Regranex (Beclapermin) |
Lower Extremity Diabetic Neuropathic Ulcers |
Infection, Cellulitis, Osteomyelitis, Erythematous Rashes |
Approved |
|
Medical Devices |
|
|
|
|
Clinical Diagnostics |
|
|
|
|
Immunoassays |
|
|
|
|
Reagents |
|
|
|
|
Test Kits |
|
|
|
|
Special/Immuno Chemistry |
|
|
|
|
Creutzfeldt-Jakob Disease (Mad Cow Disease) |
|
|
|
|
Viral |
|
|
|
|
HTLV I/II/III |
|
|
|
| HTLV-I/II ELISA |
N/A |
|
Marketed Outside the U.S. Only |
| HTLV-III ELISA |
N/A |
|
Marketed Outside the U.S. Only |
|
Hepatitis |
|
|
|
| Anti HBS ECi |
N/A |
|
Approved |
| Anti HCV ECi |
N/A |
|
Approved |
| HBCore ELISA |
N/A |
|
Approved |
| HBsAg ECi |
N/A |
|
Approved |
| HBsAg System 2 ELISA |
N/A |
|
Approved |
| HBsAg System 3 ELISA |
N/A |
|
Marketed Outside the U.S. Only |
| HCV 3.0 ELISA |
N/A |
|
Approved |
| HCV Ag ELISA 2.0 |
N/A |
|
Marketed Outside the U.S. Only |
| RIBA HCV 3.0 SIA |
N/A |
|
Approved |
|
Human Immunodeficiency Virus (HIV) |
|
|
|
|
Serum |
|
|
|
|
EIA |
|
|
|
| HIV-1/2 ELISA |
N/A |
|
Marketed Outside the U.S. Only |
|
Microbiology |
|
|
|
|
Genetic Probes/PCR |
|
|
|
|
Automated Analyzers |
|
|
|
| Procleix Optiva System |
N/A |
|
Research/Developmental |
| Procleix System |
N/A |
|
Approved |
| Procleix Tigris System |
N/A |
|
Investigational Device Exemption (IDE) Approved / Clinical Trials |
|
Reagents |
|
|
|
|
Viral |
|
|
|
|
Hepatitis B Virus |
|
|
|
| Procleix Ultrio Assay |
Simultaneous Detection Of Human Immunodeficiency Virus Type 1 (HIV-1), Hepatitis C Virus (HCV) And Hepatitis B Virus (HBV) In Donated Blood And Plasma |
|
BLA Filed |
|
Hepatitis C Virus |
|
|
|
| Procleix HIV-1/HCV Assay |
Simultaneous Detection Of HIV-1 And hepatitis C Virus (HCV) In Plasma, Whole Blood, Organs And Tissue Donations |
|
Approved |
| Procleix Ultrio Assay |
Simultaneous Detection Of Human Immunodeficiency Virus Type 1 (HIV-1), Hepatitis C Virus (HCV) And Hepatitis B Virus (HBV) In Donated Blood And Plasma |
|
BLA Filed |
|
Human Immunodeficiency Virus (HIV) |
|
|
|
| Procleix HIV-1/HCV Assay |
Simultaneous Detection Of HIV-1 And hepatitis C Virus (HCV) In Plasma, Whole Blood, Organs And Tissue Donations |
|
Approved |
| Procleix Ultrio Assay |
Simultaneous Detection Of Human Immunodeficiency Virus Type 1 (HIV-1), Hepatitis C Virus (HCV) And Hepatitis B Virus (HBV) In Donated Blood And Plasma |
|
BLA Filed |
|
West Nile Virus |
|
|
|
| Procleix West Nile Virus Assay |
Detection Of West Nile Virus In Donated Blood, Plasma And Organs |
|
Approved |
|
Transfusion Medicine |
|
|
|
|
Immunohematology |
|
|
|
|
Blood Conversion System |
|
|
|
| A-ECO Blood System |
N/A |
|
Clinical Trials |
|
Outsourced Services |
|
|
|
|
Development/Manufacturing Services |
|
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
|
Pharmaceuticals |
|
|
|
|
Biologics |
|
|
|
|
Drug Discovery Services |
|
|
|
|
Target Discovery/Validation |
|
|
|
|
Services |
|
|
|
